

[63] DEVELOPMENT OF FIRST IN CLASS HIGH AFFINITY SMALL MOLECULE ANTAGONIST OF A NOVEL CANCER TARGET CRITICAL FOR TUMOR CELL MIGRATION AND SURVIVAL

Amnon Peled, CEO, Biokine Therapeutics , Israel

- **Investment Rational**
Biokine therapeutics is developing novel cancer therapeutics with a focus on targeting tumor migration and proliferation. Current pipeline includes **BL-8040 (BKT140)**, Best in-class CXCR4 receptor inhibitor currently in Phase IIb for Leukemia, Phase III for Stem Cell Mobilization and Phase II for cancer immunotherapy. BL-8040 is licensed to BioLineRx (NASDAQ:BLRX). Highly experience team in cancer drug development.
- **Business Strategy**
Planned IND and Initiation of clinical trials by Q3/2020 in selected cancer indications. Looking for investment from specials pharma/VC.
- **Core Technology**
BKT300, first in-class, high affinity, small molecule antagonist of a novel cancer target critical for tumor cell migration and proliferation. Inhibits cancer cell migration and cytokinesis and induces selective apoptotic cell death.
- **Product Profile/Pipeline**

BKT300 is Novel synthetic small molecule identified by unique phenotypic screen. It is highly selective inhibitor of hematological and solid tumors cancer cell migration and arrests proliferation of cancer cells at G2/M cell cycle checkpoint and induces their apoptotic cell death through the caspase 3 pathway. BKT300 inactivates its target function as a modulator of microtubules and actin organization and upon binding its target protein it induces the degradation of CDC25c and upregulates p21, proteins that are critical for cell cycle progression In-vivo, BKT300 administration significantly inhibits tumor growth in AML, pancreatic, HCC and lung tumor mice models.

- **What's Next?**
R&D- MOA studies together with preclinical studies that will lead BKT300 to Phase I/II in selected cancer indications. Raising financials to support pre and clinical development.

